Columbus、OHにおける膀胱癌の臨床試験
Columbusとその周辺地域（約30マイル以内）の拠点で、膀胱癌に関する19件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
被験者募集中第3相
- Ohio State University Comprehensive Cancer Center, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- 他8件
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
被験者募集中第2相
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- Doctors Hospital, Columbus
- 他1件
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- 他11件
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
被験者募集中第1相
- Ohio State University, Columbus
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
被験者募集中第2相
- Ohio State University, Columbus
- Central Ohio Urology Group (US Urology Partners), Gahanna · 7マイル先
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- The Ohio State University (OSU), Columbus
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
被験者募集中第3相
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- The Ohio State University Comprehensive Cancer Center, Columbus
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
被験者募集中第1/2相
- Central Ohio Urology Group, Gahanna · 7マイル先
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
被験者募集中観察研究
- The Ohio State University, Columbus
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
被験者募集中第2/3相
- The James Outpatient Care West Campus, Columbus
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
被験者募集中第2相
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
被験者募集中第2相
- Ohio State University Hospital, Columbus
- Ohio State University, Columbus
- OSU Wexner Medical Center & James Cancer Hospital, Columbus
- 他2件
Blue Light Cystoscopy With Cysview® Registry
被験者募集中観察研究
- Ohio State University Wexner Medical Center, Columbus
- Ohio State University, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Columbus
他の都市における膀胱癌の試験
- New York City, NY35件の研究
- Nashville, TN31件の研究
- Houston, TX31件の研究
- Dallas, TX27件の研究
- Boston, MA26件の研究
- Washington, DC26件の研究
- Los Angeles, CA24件の研究
- Baltimore, MD24件の研究
- St. Louis, MO22件の研究
- Philadelphia, PA21件の研究
- Seattle, WA21件の研究
- Edison, NJ21件の研究
Columbusにおける他の研究
- 非小細胞肺癌56件の研究
- 乳がん39件の研究
- 卵巣がん39件の研究
- がん（全種類）38件の研究
- 肺がん37件の研究
- 急性骨髄性白血病35件の研究
- 慢性リンパ性白血病28件の研究
- 転移性癌27件の研究
- 子宮内膜がん25件の研究
- 大腸癌24件の研究
- 前立腺がん24件の研究
- 多発性骨髄腫24件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。